Molecular imaging of thrombus formation at initial stage requires a robust thrombus-specific contrast agent with high sensitivity. In this study, we report a novel P-selectin-targeted paramagnetic molecular imaging agent and the agent's potential to sensitively detect occult microthrombi on the intimal surface of endothelium. Platelet clots and blood clots targeted in vitro with paramagnetic nanoparticles presented a highly detectable, homogeneous T1-weighted contrast enhancement that was improved with increasing gadolinium level. In vivo contrast enhancement under part of circulation conditions was assessed in dogs. The micro-thrombi around the femoral vein of dog demonstrated higher signal intensities than the control clots and the adjacent muscle. Histology was performed on regions likely to contain thrombus as indicated by MRI. These results suggest that molecular imaging of P-selectin-targeted paramagnetic nanoparticles can provide sensitive detection and localization of P-selectin and may allow for early, direct identification of microthrombi, leading to early diagnosis.
Introduction
Venous thromboembolism (VTE), manifested as either deep venous thrombosis (DVT) or pulmonary embolism (PE), is a common medical problem occurring either in isolation or as a complication of other diseases or medical procedures. 1 The hemostatic system is made up of 2 distinct but interlocking components: platelets and the coagulation proteins. Multiple factors and events must occur in a highly regulated fashion for a blood clot to form. P-selectin is one of the factors. 2, 3 Activation of platelets or impaired endothelium leads to the exposure of P-selectin on the surface of platelets, and simultaneously endothelial cells degranulate with the rapid translocation of P-selectin to the plasma membrane. [4] [5] [6] [7] Accumulating lines of evidence now invoke a role for P-selectin and its ligand to accumulate tissue factor and subsequent generate fibrin within the platelet thrombus.
Although a variety of invasive imaging modalities such as intravascular ultrasound elastography, 8 x-ray angiography 9 have been used for imaging thrombus, magnetic resonance imaging (MRI) has emerged as the most promising noninvasive imaging technique for the in vivo detection and characterization of thrombogenesis. 10, 11 Recent advances in the field of molecular imaging have led to the development of novel paramagnetic and super-paramagnetic-targeted MR contrast agents that bind exclusively to molecules such as albumin, fibrin, or angiogenesis markers. 12, 13 P-selectin is expressed abundantly in both the activated platelets and stimulated endothelial cells and it is also the molecule marker in this study. P-selectin is a 140 kd transmembrane glycoprotein, and lectin-epidermal growth factor (L-EGF) domain of P-selectin is the critical unit for leukocyte binding. [14] [15] [16] Therefore, we developed a monoclonal antibody targeting to L-EGF domain and developed a novel MR contrast agent conjugated with the antibody. Because of the inherently low sensitivity of MR contrast enhancement technology, a relatively high target molecule concentration is necessary for adequate signal amplification. 17 The contrast agent for molecular imaging is required to allow for enhanced, sensitive detection and quantification of occult microthrombi within the intimal surface of endothelium, and provide direct, early, and specific evidence for thrombus diagnosis.
The objective of the current study was to demonstrate the potential of a P-selectin targeted, paramagnetic nanoparticulate contrast agent to specifically image thrombus deposits both in vitro and in vivo at a clinically relevant magnetic field strength (1.5 T). We evaluated the capability of the novel contrast agent to transport high payloads of gadolinium diethylene-triamine-pentaacetic acid (Gd-DTPA) and estimated the T1 relaxivities relative to particle number, reflecting their utility as a targeted molecular imaging.
Methods (Gd-DTPA) n -Bovine Serum Albumin Preparation
Bovine serum albumin (BSA) 50 mg was dissolved in 2.5 mL 0.2 mol/L NaHCO 3 /Na 2 CO 3 buffer (pH 9.6), then Gd-DTPA (prepared by Department of Radiopharmacy, Pharmacy College of Fu Dan University) was added while stirring in ice bath. The reaction reached the end point after stirring for 20 hours at room temperature. The (Gd-DTPA) n -BSA was separated and purified by SephadexG-25 (Sigma Chemical Co., St. Louis, MO, USA) with 0.01 mol/L phosphate buffered saline (PBS; pH 7.4) as running buffer. The mixture solution of condensed (Gd-DTPA) n -BSA and excess Gd chloride was stirred overnight at room temperature. Unbound Gd was removed by SephadexG-25 as above.
Preparation of a PsL-EGFmAb-BSA 4 -(Gd-DTPA) n MRI Contrast Agent
Anti-human-P-selectin lectin-EGF domain monoclonal antibody (PsL-EGFmAb) was produced and purified by the Department of Nephrology, Ruijin hospital, Shanghai Jiao Tong University School of Medicine. The antibody was diluted to a final concentration of 1.5 mg/mL in 0.1 mol/L NaHCO 3 /Na 2 CO 3 buffer (pH 9.6). After adding (Gd-DTPA) n -BSA[0], the solution was left to stir overnight at room temperature. PsL-EGFmAb-BSA4-(Gd-DTPA) n were separated and purified by Sepharose CL-4B (Sigma). It was filtered by 0.22 mm aseptic filtration, condensed, and stored at 4 C.
Properties of PsL-EGFmAb-BSA 4 -(Gd-DTPA) n MRI Contrast Agent
The concentration of Gd in contrast agent was measured by inductively coupled plasma-atomic emission spectrometry (ICP-AES), and the purity of contrast agent was analyzed by high-performance liquid chromatography (HPLC). The number of Gd complexes per nanoparticle was calculated from the ratio of the concentrations of Gd and nanoparticles in the emulsion.
The immunocompetence of contrast agent was analyzed by competitive enzyme-linked immunosorbent assay (ELISA), using a P-selectin (R&D Systems, Minneapolis, MN, USA) as a coating antigen, PsL-EGFmAb-BSA 4 -(Gd-DTPA) n , and horseradish peroxidase-conjugated PsL-EGFmAb as competitive antibody.
PsL-EGFmAb-BSA 4 -(Gd-DTPA) n , PsL-EGFmAb-BSA 3 -(Gd-DTPA) n , BSA-(Gd-DTPA) n , and Gd-DTPA were imaged in MRI with multiple proportion (doubledistilled [dd] H 2 O as control).
Magnetic Resonance Imaging of Targeted Clots In Vitro
In vitro imaging was carried out by 2 separate experiments. Platelet clots and blood clots were separately produced by combining plasma with 100 mmol/L CaCl 2 (3:1 vol/vol) and 5 U thrombin (Dade Behring, Marburg, Germany). In preparing the platelet clots, 80, 60, and 40 mL contrast reagents were added into 500 mL platelet-rich plasma; 80 mL Gd-DTPA and 80 mL PBS were added to the same volume plasma as negative control and blank, respectively. Clots were serially incubated 1 hour at 37 C to complete the binding and were rinsed 3 times with sterile saline after incubation to remove any unbound reactants.
In second in vitro imaging experiment, 150 mL contrast reagent was added to 1 mL blood. The control was the same as above. Targeted human blood clots that were suspended in blood in plastic tubes were imaged. Contrast-to-noise (CNR) between the clot and blood was calculated as the difference of the signal intensity (SI) between a region of interest within the targeted clot and a region of interest in a control clot or the surrounding liquid.
Animal Model of Venous Thrombosis
The concept of the P-selectin-targeted, paramagnetic nanoparticles to enhance the detect ability of clots in a flowing intravascular environment was evaluated in dogs. Six dogs (%12 kg) were pretreated with tranexamic acid (0.25 g/h) to inhibit endogenous thrombolysis. Each animal was anesthetized (sodium pentobarbitone) and prepared for surgery. The left femoral vein of animal was exposed. Injury was performed at the femoral vein with a variable length of 0.5 to 1.5 cm in a random manner. Nylon monofilament (4-0) was used to destroy the endothelium. Approximately 5 minutes after repeated serial vessel damage, flow was reestablished. Injury was always performed with the same Nylon monofilament and by the same operator to minimize variability.
Magnetic Resonance Imaging of Targeted Clots In Vivo
After operation, 2 mL 1.5 mg/mL (Gd-DTPA) n -BSA 4 -PsL-EGFmAb or Gd-DTPA (as control) was infused into the blood vessel of each dog. Because the P-selectin was expressed abundantly on the activated platelets and stimulated endothelial cells, the contrast agent was acquired bolus injection as soon as the operation finished. Dogs were sedated with sodium pentobarbitone (as described earlier) and were imaged in a supine position with a 1.5-T MRI system. The injured femoral vein and the contralateral normal femoral vein were imaged 30 minutes after bolus injection. Two additional dogs were used to compare P-selectin-targeted contrast agent and a conventional Gd-DTPA for thrombus detection.
Magnetic Resonance Imaging Experiments
The imaging parameters of MRI in vitro were the same as in vivo. All imaging experiments were performed with a 1.5-T clinical MR imager (Echo Twin-speed by General Electric Inc, Fairfield, CT, USA) with a standard surface coil (3 inch 
Histopathology
Thrombus detection was performed by gross histological analysis of the sectioning and immunohistological analysis. All sections (slice thickness ¼ 5 mm, every 3 mm, cryostat sectioned) of the femoral vein were stained with hematoxylin and eosin and assessed visually for the presence or absence of thrombus.
Results

Properties of PsL-EGFmAb-BSA 4 -(Gd-DTPA) n MRI Contrast Agent
The concentration of Gd in (Gd-DTPA) n -BSA 4 -PsL-EGFmAb is 44 mg/kg (molecular weight of Gd is 157.25), detected by ICP-AES. We calculate that 1 PsL-EGFmAb binds with 70 to 100 Gd. The competitive ELISA results show that the immunocompetence of contrast agent is consistent when PsL-EGFmAb binds with 4 (Gd-DTPA) n -BSA (Figure 1 ). Through the BSA, PsL-EGFmAb can bind 280 to 400 Gd, which do not affect the immunocompetence of PsL-EGFmAb. The purity level of (Gd-DTPA) n -BSA 4 -PsL-EGFmAb was 98%, determined by HPLC. The capacity of these nanoparticles to support high paramagnetic payloads is of paramount importance to the efficacy of these agents when they are used for molecular imaging of biochemical epitopes.
Relaxivities of the Paramagnetic Nanoparticles
T1 relaxivities of the PsL-EGFmAb-BSA 4 -(Gd-DTPA) n paramagnetic formulation determined at the 3 fixed magnetic field strengths clearly reveal the superior performance of the PsL-EGFmAb-BSA 4 -(Gd-DTPA) n nanoparticles. At 1.5 T, a typical medical imaging field strength, PsL-EGFmAb-BSA 4 -(Gd-DTPA) n , PsL-EGFmAb-BSA 3 -(Gd-DTPA) n , BSA-(Gd-DT-PA) n , and Gd-DTPA were imaged in 12 points (dd H 2 O as control). PsL-EGFmAb-BSA 4 -(Gd-DTPA) n showed a stronger signal at the same concentration of the antibody (Figure 2 ). From the Figure 2 , we found that high concentration of contrast agent has no signal. However, as the solution increased in concentration, the strength of SI increased to a certain level before dropping off. The 1:64 diluted contrast agent has the most SI, and the SI starts to decrease from 1:128 dilution.
PsL-EGFmAb-BSA 4 -(Gd-DTPA) n MRI for Thrombus Detection In Vitro
Magnetic resonance imaging results demonstrated the significant contrast enhancement produced by the P-selectin-specific nanoparticles targeted to human platelet clots in vitro at clinically relevant field strength (1.5 T). With a typical low-resolution clinical imaging protocol, the platelet clots targeted with nanoparticles presented a homogeneous T1-weighted contrast enhancement, which improved by increasing Gd level (Figure 3 ). The amount of Gd-DTPA was not associated with a significant improvement in thrombus detection, as confirmed by CNR values. Relative SI and normalized CNR were significantly increased at different quantity of contrast reagent (P < 0.01). The SI of P-selectin-specific nanoparticles targeted to human blood clots is higher than control, and the appearance of human blood clots can be easily seen (Figure 4 ).
PsL-EGFmAb-BSA 4 -(Gd-DTPA) n MRI for Thrombus Detection In Vivo
The magnitude of contrast enhancement expected in vivo with part of circulation conditions was evaluated in dogs. Control or 2 mL 1.5 mg/mL PsL-EGFmAb-BSA 4 -(Gd-DTPA) n was targeted in situ as a single-step system to thrombus created within the femoral vein. Thrombus was imaged with 3D T1-weighted, fat-suppressed, fast-gradient echo sequence, and the results showed that the targeted clot was markedly enhanced by the P-selectin-specific paramagnetic nanoparticles compared with control thrombus (Figures 5A and B) .
Corresponding gradient-echo images revealed a selective enhancement of the treated clot, yielding higher SI than the control clot and the adjacent muscles, but lower than the bright fat signal. On T1-weighted gradient-recalled-echo images with fat suppression, the targeted clot showed the higher SI.
Thirty minutes after the administration of PsL-EGFmAb-BSA 4 -(Gd-DTPA) n , signal enhancement in the thrombus around the femoral vein was observed ( Figure 5A) , with good differentiation from arterial blood and thrombus-free vessel wall. As expected, no change was seen in the uninjured veins (controls).
Visible agreement in location was found with histopathology ( Figure 6 ). P-selectin immunostaining of the excised vessel and clot confirmed the abundance and localization of P-selectin corresponding to the contrast enhancement in vivo.
Discussion
In this study, we demonstrated the novelty and superiority of contrast-enhanced MRI with a P-selectin-targeted contrast agent in vitro and in vivo for thrombus detection at the early stage of coagulation. This unique agent can carry high Gd-DTPA payloads for high detection sensitivity and is different from the fibrin-target contrast agent that was reported. 18 The latter aimed directly at the fibrin, which is the product of blood clotting; however, PsL-EGFmAb-BSA4-(Gd-DTPA) n aimed at the P-selectin, which was expressed abundantly on the surface of activated platelets and stimulated endothelial cells. The fibrin deposition in venous thrombi is associated with the expressed P-selectin, 19, 20 and P-selectin plays a significant role of thrombus formulation. 21 Therefore, the PsL-EGFmAb-BSA4-(Gd-DTPA) n can be used for thrombus detection at an early stage.
Sensitive MR molecular imaging of microthrombi requires a high-avidity, thrombus-specific MR contrast agent with high paramagnetic impact. Using the BSA to formulate the Gd polymer, 22, 23 we reported that the contrast agent can bear 280 to 400 Gd molecules. In molecular imaging applications, the paramagnetic influence of each binding complex is critical. Magnetic resonance imaging of PsL-EGFmAb-BSA4-(Gd-DTPA) n showed that remarkable SI and platelets clots or blood clots imaged at 1.5 T are detectable despite the expected resolution limitation. The SI was not affected by the accumulation of fibrin but was enhanced with the increasing amount of P-selectin-targeted contrast agent. PsL-EGFmAb-BSA 4 -(Gd-DTPA) n produced information on thrombus formulation at early time, highlighting the P-selectin-rich areas, activation platelets, and stimulated endothelial cells.
To confirm the conjugation with activated platelets and stimulated endothelial cells in vivo, we injected PsL-EGFmAb-BSA 4 -(Gd-DTPA) n to parts of the femoral vein in the dog. The microthrombi around the femoral vein of canine demonstrated higher signal intensities than the normal control and the adjacent muscle, but lower than the bright fat signals. It may be due to the insufficient level of PsL-EGFmAb-BSA 4 -(Gd-DTPA) n injection. However, the experiment results demonstrated that PsL-EGFmAb-BSA 4 -(Gd-DTPA) n can efficiently combine with activation platelets and stimulated endothelial cells in vivo, showing the specificity of imaging.
The development of a stable, targeted MRI contrast agent presents a wide variety of the opportunities for improving diagnosis. Unlike PsL-EGF-mAb-BSA 4 -(Gd-DTPA) n , Gd-DTPA is a nonspecific contrast agent that disperses to the intravascular and interstitial spaces by diffusion. 24 It does not allow for thrombus enhancement. Interestingly, no uptake of Gd-DTPA within the thrombus was noted at any imaging time in our study, in contrast to the perivascular muscle enhancement due to Gd-DTPA diffusion.Therefore,PsL-EGFmAb-BSA 4 -(Gd-DTPA) n provides an effective way to diagnose early thrombus formations. Because thrombosis is a dynamic process, with thrombus material of different ages forming a layered structure due to successive mural deposition, P-selectin-targeted, contrast-enhanced MRI may be used to diagnose thrombi only at the stage of platelets activated. Acute coronary syndromes, stroke, deep vein thrombosis complicated by PE, and arterial fibrillation with a high incidence of various cardiac manifestations result from thrombus formation in different vascular beds after either plaque rupture/erosion or increased blood thrombogenicity. 25, 26 Therefore, a noninvasive modality with a P-selectin-targeted contrast agent might be ideal for in vivo detection of all thrombi formation at an earlystage. In addition, this novel contrast may benefit patients with tendency of DVT and facilitate detection of hypercoagulabale state at an early stage. The enhancement of P-selectin expression in the ruptured blood vessels with targeted paramagnetic nanoparticles was readily apparent, in contradistinction to the control specimens. Similar early diagnosis of ruptured intimal and/or activated platelet Pselectin expression in a patient with thrombosis may someday prompt early anticoagulant therapy.
In summary, we reported a novel P-selectintargeted paramagnetic molecular imaging contrast agent that enhances the sensitivity of in vitro and in vivo clots detected by MRI. This unique agent, because of its strong MR contrast impact, has the ability to enhance the detection of intravascular clots. Emerging molecular MR imaging technologies, such as those with paramagnetic nanoparticles, may provide early direct diagnosis of thrombus in patients with heralding symptoms and facilitate early therapeutic intervention. However, the agent we reported here may have a limitation in detecting thrombosis which is not mediated by P-selectin. Figure 5 . A, Axial magnetic resonance imaging of thrombi in femoral vein targeted with P-selectin-specific paramagnetic nanoparticles demonstrating dramatic T1-weighted contrast enhancement in gradient-echo image (arrow) on left without flow deficit (arrow) of thrombus. Note the benefit of using the P-selectin-targeted MR contrast agent for thrombus detection. Thrombus around the vessel wall has higher signal than the adjacent muscle. Accurate detection and localization of the thrombus were successful in nonocculsive thrombi. B, Control thrombus in contralateral femoral vein imaged as in A. Figure 6 . Results of immunohistological analysis.
